BioRegenx Statistics
Total Valuation
BioRegenx has a market cap or net worth of 10.08 million. The enterprise value is 12.22 million.
| Market Cap | 10.08M |
| Enterprise Value | 12.22M |
Important Dates
The next estimated earnings date is Monday, April 27, 2026.
| Earnings Date | Apr 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioRegenx has 969.02 million shares outstanding. The number of shares has increased by 5.19% in one year.
| Current Share Class | 969.02M |
| Shares Outstanding | 969.02M |
| Shares Change (YoY) | +5.19% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 12.36% |
| Owned by Institutions (%) | n/a |
| Float | 255.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.43 |
| PB Ratio | -2.22 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 336.88 |
| P/OCF Ratio | 258.59 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.92 |
| EV / Sales | 6.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 408.59 |
Financial Position
The company has a current ratio of 0.06
| Current Ratio | 0.06 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 74.03 |
| Interest Coverage | -1.73 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -70.55% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 14.20% |
| Weighted Average Cost of Capital (WACC) | -7.55% |
| Revenue Per Employee | 370,903 |
| Profits Per Employee | -308,714 |
| Employee Count | 5 |
| Asset Turnover | 4.03 |
| Inventory Turnover | 3.22 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.70% in the last 52 weeks. The beta is -2.87, so BioRegenx's price volatility has been lower than the market average.
| Beta (5Y) | -2.87 |
| 52-Week Price Change | -3.70% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 44.42 |
| Average Volume (20 Days) | 76,766 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.16 |
Income Statement
In the last 12 months, BioRegenx had revenue of 1.85 million and -1.54 million in losses. Loss per share was -0.00.
| Revenue | 1.85M |
| Gross Profit | 1.50M |
| Operating Income | -518,991 |
| Pretax Income | -1.54M |
| Net Income | -1.54M |
| EBITDA | -443,916 |
| EBIT | -518,991 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 69,383 in cash and 2.21 million in debt, with a net cash position of -2.15 million or -0.00 per share.
| Cash & Cash Equivalents | 69,383 |
| Total Debt | 2.21M |
| Net Cash | -2.15M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -4.54M |
| Book Value Per Share | -0.00 |
| Working Capital | -3.82M |
Cash Flow
In the last 12 months, operating cash flow was 38,972 and capital expenditures -9,057, giving a free cash flow of 29,915.
| Operating Cash Flow | 38,972 |
| Capital Expenditures | -9,057 |
| Depreciation & Amortization | 75,075 |
| Net Borrowing | 33,098 |
| Free Cash Flow | 29,915 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 81.08%, with operating and profit margins of -27.99% and -83.23%.
| Gross Margin | 81.08% |
| Operating Margin | -27.99% |
| Pretax Margin | -83.23% |
| Profit Margin | -83.23% |
| EBITDA Margin | -23.94% |
| EBIT Margin | -27.99% |
| FCF Margin | 1.61% |
Dividends & Yields
BioRegenx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.19% |
| Shareholder Yield | -5.19% |
| Earnings Yield | -15.32% |
| FCF Yield | 0.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioRegenx has an Altman Z-Score of -135.64 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -135.64 |
| Piotroski F-Score | 5 |